非酒精性脂肪性肝病的治疗研究进展  

Progress in the treatment of nonalcoholic fatty liver disease

作　　者：周谦 苏娟[1] 季梦遥[1] ZHOU Qian;SU Juan;JI Mengyao(Department of Gastroenterology,Renmin Hospital of Wuhan University,Hubei Province,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院消化Ⅰ科

出　　处：《中国医药导报》2020年第6期26-29,共4页China Medical Herald

基　　金：国家自然科学基金资助项目（81901817）

摘　　要：非酒精性脂肪性肝病(NAFLD)是发达国家中最常见性肝病。其目前的治疗策略侧重于通过生活方式管理来减轻体重,以及改善其代谢综合征的组分。已有的各种假设的致病机制,成为开发具有有效治疗非酒精性脂肪性肝炎(NASH)患者潜力的新药物靶点。利用这些实验药物和靶向特定机制途径的分子来有效治疗NASH,目前,已有许多药物的临床试验正在进行中。本文主要就NAFLD的治疗现状以及新药研究进展作一概述。Nonalcoholic fatty liver disease(NAFLD)is the most common liver disease in developed countries.The current treatment strategy focused on weight lose through lifestyle management and on the optimization of the components of metabolic syndrome.Various hypothetical pathogenic mechanisms have been proposed to develop new drug targets with potential for effective treatment of non-alcoholic steatohepatitis(NASH)patients.These experimental drugs and molecules that target specific mechanism pathways are used to effectively treat NASH.Currently,clinical trials of many drugs are underway.This article focuses on the current status of treatment of NAFLD and the progress of new drug research.

关 键 词：非酒精性脂肪性肝病 治疗 新药 致病机制 

分 类 号：R575.5[医药卫生—消化系统]